Brachytherapy for liver cancer
The BEBIG company became the first in Russia and the third in the world to launch the production and sale of microspheres based on yttrium-90
The research and production company "BEBIG" LLC has received an updated registration certificate for the production and sale of nanostructured microspheres based on yttrium-90 used in the treatment of both primary and metastatic liver lesions.
This means the formal start of industrial production on the territory of the Russian Federation and the sale of ready-made batches of microspheres to medical institutions for use in radiotherapy of primary and metastatic liver tumors. Currently, the technology of treatment of inoperable patients with liver cancer is recognized as the most effective and has no alternatives. In total, three companies in the world own this microsphere production technology: Canadian MDS Nordion, Australian Sirtex, and now the Russian company BEBIG.
"We have done a lot of work together with the Ministry of Health of the Russian Federation and the A.F. Tsyba Medical Radiological Research Center (a branch of the Federal State Budgetary Institution "NMIC of Radiology" of the Ministry of Health of the Russian Federation in Obninsk), so that Russian patients could get priority access to the most modern and effective treatment methods. We have not only managed to realize industrial production in our country and become the third company in the world for the production of microspheres, but also to reduce the cost of the therapeutic dose of the drug three times compared to its foreign counterpart," said Kirill Mayorov, CEO of BEBIG LLC.
In the Russian Federation, about 8 thousand new cases of primary liver cancer are registered annually. Of these, radical surgery is possible only in 20% of cases. Over the past twenty years, the leading clinics in the world have been actively using the method of radioembolization in the treatment of liver cancer and liver metastases, based on the introduction of microspheres containing a radionuclide drug into the vessels feeding the tumor. This method makes it possible to stop tumor growth in 90% of patients and increases life expectancy by 4-5 times compared to other standard methods of treatment.
According to the BEBIG company, the launch of mass production of microspheres will meet the needs of not only patients with primary liver lesions (hepatocellular carcinoma). Radioembolization is used in the treatment of metastatic liver lesions caused by tumors of other localizations, for example, metastases of breast cancer, colorectal cancer and neuroendocrine tumors that have spread to the liver. Microspheres with the radioactive isotope yttrium-90 are used as palliative care when it is impossible to completely cure cancer, but it is possible to slow down the growth of the tumor and alleviate the symptoms of the disease, providing a higher quality of life for the patient. In addition, radioembolization is used in cases where surgical interventions or liver transplantation are contraindicated for patients for various reasons. This method is also used in combination with other types of treatment, for example, with chemotherapy to maximize the effect of destroying cancer cells. According to preliminary estimates, the annual needs of Russian clinics for microspheres containing yttrium-90 are about 1,000 individual doses.
Portal "Eternal youth" http://vechnayamolodost.ru